Alternative mutational pathways to intermediate resistance to vancomycin in methicillin-resistant Staphylococcus aureus.

BACKGROUND  We used 2 in vitro experimental systems to compare phenotypic and genotypic changes that accompany selection of mutants of methicillin-resistant Staphylococcus aureus (MRSA) strain JH1 with low-level vancomycin resistance similar to the type found in vancomycin-intermediate S. aureus (VISA). METHODS  The previously described MRSA strain JH1 and its vancomycin-intermediate mutant derivative JH2, both of which were recovered from a patient undergoing vancomycin chemotherapy, were used in this study. Mutants of JH1 were selected in vitro by means of a pharmacokinetic/pharmacodynamic (PK/PD) model of simulated endocardial vegetations (SEVs) and by exposure to vancomycin in laboratory growth medium. Phenotypic abnormalities of JH1 mutants generated by each in vitro experimental system were compared to those of JH2, and whole genomes of 2 in vitro JH1 mutants were sequenced to identify mutations that may be associated with an increased vancomycin minimum inhibitory concentration. RESULTS  JH1R1 was selected from the PK/PD model, and JH1R2 was selected in laboratory growth medium. Both mutants displayed reduced vancomycin and daptomycin susceptibility and phenotypic alterations (eg, thicker cell walls and abnormal autolysis) that are typical of in vivo VISA mutants. Genome sequencing of JH1R1 identified point mutations in 4 genes, all of which were different from the mutations described in JH2, including 1 mutation in yycG, a component of the WalKR sensory regulatory system. Sequencing of the JH1R2 genome identified mutations in 7 genes, including 2 in rpoB. CONCLUSION  Our findings indicate that JH1 is able to develop VISA-type resistance through several alternative genetic pathways.

[1]  R. Daum,et al.  VraT/YvqF Is Required for Methicillin Resistance and Activation of the VraSR Regulon in Staphylococcus aureus , 2012, Antimicrobial Agents and Chemotherapy.

[2]  F. Lowy,et al.  Contribution of Selected Gene Mutations to Resistance in Clinical Isolates of Vancomycin-Intermediate Staphylococcus aureus , 2012, Antimicrobial Agents and Chemotherapy.

[3]  D. Ward,et al.  Serine/threonine phosphatase Stp1 contributes to reduced susceptibility to vancomycin and virulence in Staphylococcus aureus. , 2012, The Journal of infectious diseases.

[4]  C. Arias,et al.  Evaluation of Standard- and High-Dose Daptomycin versus Linezolid against Vancomycin-Resistant Enterococcus Isolates in an In Vitro Pharmacokinetic/Pharmacodynamic Model with Simulated Endocardial Vegetations , 2012, Antimicrobial Agents and Chemotherapy.

[5]  Boris M. Hartmann,et al.  Genetic Pathway in Acquisition and Loss of Vancomycin Resistance in a Methicillin Resistant Staphylococcus aureus (MRSA) Strain of Clonal Type USA300 , 2012, PLoS pathogens.

[6]  M. Rybak,et al.  Evaluation of Telavancin Activity versus Daptomycin and Vancomycin against Daptomycin-Nonsusceptible Staphylococcus aureus in an In Vitro Pharmacokinetic/Pharmacodynamic Model , 2011, Antimicrobial Agents and Chemotherapy.

[7]  Torsten Seemann,et al.  Evolution of Multidrug Resistance during Staphylococcus aureus Infection Involves Mutation of the Essential Two Component Regulator WalKR , 2011, PLoS pathogens.

[8]  Martin Goodson,et al.  Stampy: a statistical algorithm for sensitive and fast mapping of Illumina sequence reads. , 2011, Genome research.

[9]  L. Cui,et al.  Impact of rpoB Mutations on Reduced Vancomycin Susceptibility in Staphylococcus aureus , 2011, Journal of Clinical Microbiology.

[10]  T. Fennell,et al.  Analyzing and minimizing PCR amplification bias in Illumina sequencing libraries , 2011, Genome Biology.

[11]  Paul D. R. Johnson,et al.  Reduced Vancomycin Susceptibility in Staphylococcus aureus, Including Vancomycin-Intermediate and Heterogeneous Vancomycin-Intermediate Strains: Resistance Mechanisms, Laboratory Detection, and Clinical Implications , 2010, Clinical Microbiology Reviews.

[12]  K. Lewis,et al.  Persister cells. , 2010, Annual review of microbiology.

[13]  Richard Durbin,et al.  Sequence analysis Fast and accurate short read alignment with Burrows – Wheeler transform , 2009 .

[14]  L. Cui,et al.  Contribution of vraSR and graSR Point Mutations to Vancomycin Resistance in Vancomycin-Intermediate Staphylococcus aureus , 2009, Antimicrobial Agents and Chemotherapy.

[15]  Richard Durbin,et al.  A large genome center's improvements to the Illumina sequencing system , 2008, Nature Methods.

[16]  David Hernández,et al.  De novo bacterial genome sequencing: millions of very short reads assembled on a desktop computer. , 2008, Genome research.

[17]  H. Nelis,et al.  Comparison of multiple methods for quantification of microbial biofilms grown in microtiter plates. , 2008, Journal of microbiological methods.

[18]  P. Ward,et al.  Different bacterial gene expression patterns and attenuated host immune responses are associated with the evolution of low-level vancomycin resistance during persistent methicillin-resistant Staphylococcus aureus bacteraemia , 2008, BMC Microbiology.

[19]  G. Bierbaum,et al.  Role of insertion elements and yycFG in the development of decreased susceptibility to vancomycin in Staphylococcus aureus. , 2007, International journal of medical microbiology : IJMM.

[20]  Alexander Tomasz,et al.  Tracking the in vivo evolution of multidrug resistance in Staphylococcus aureus by whole-genome sequencing , 2007, Proceedings of the National Academy of Sciences.

[21]  A. Bayer,et al.  Low-Level Resistance of Staphylococcus aureus to Thrombin-Induced Platelet Microbicidal Protein 1 In Vitro Associated with qacA Gene Carriage Is Independent of Multidrug Efflux Pump Activity , 2006, Antimicrobial Agents and Chemotherapy.

[22]  J. Adler-Moore,et al.  Functional Interrelationships between Cell Membrane and Cell Wall in Antimicrobial Peptide-Mediated Killing of Staphylococcus aureus , 2005, Antimicrobial Agents and Chemotherapy.

[23]  S. Richter,et al.  The in vitro activity of daptomycin against Staphylococcus aureus and Enterococcus species. , 2003, The Journal of antimicrobial chemotherapy.

[24]  A. Tomasz,et al.  Evolution of a Vancomycin-Intermediate Staphylococcus aureus Strain In Vivo: Multiple Changes in the Antibiotic Resistance Phenotypes of a Single Lineage of Methicillin-Resistant S. aureus under the Impact of Antibiotics Administered for Chemotherapy , 2003, Journal of Clinical Microbiology.

[25]  G. Eliopoulos,et al.  Accessory Gene Regulator (agr) Locus in Geographically Diverse Staphylococcus aureus Isolates with Reduced Susceptibility to Vancomycin , 2002, Antimicrobial Agents and Chemotherapy.

[26]  P. Taylor,et al.  Methicillin Resistance in Staphylococcus Aureus: Mechanisms and Modulation , 2002, Science progress.

[27]  R. Akins,et al.  Bactericidal Activities of Two Daptomycin Regimens against Clinical Strains of Glycopeptide Intermediate-ResistantStaphylococcus aureus, Vancomycin-ResistantEnterococcus faecium, and Methicillin-ResistantStaphylococcus aureus Isolates in an In Vitro Pharmacodynamic Model with Simulated Endocardial V , 2001, Antimicrobial Agents and Chemotherapy.

[28]  S. Stepanović,et al.  A modified microtiter-plate test for quantification of staphylococcal biofilm formation. , 2000, Journal of microbiological methods.

[29]  Mary Jane Ferraro,et al.  Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically : approved standard , 2000 .

[30]  A. Bayer,et al.  In Vitro Antibacterial Activities of Platelet Microbicidal Protein and Neutrophil Defensin against Staphylococcus aureus Are Influenced by Antibiotics Differing in Mechanism of Action , 1999, Antimicrobial Agents and Chemotherapy.

[31]  Y. Fukuchi,et al.  Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin , 1997, The Lancet.

[32]  D H Persing,et al.  Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing , 1995, Journal of clinical microbiology.

[33]  A. Tomasz,et al.  Suppression of autolysis and cell wall turnover in heterogeneous Tn551 mutants of a methicillin-resistant Staphylococcus aureus strain , 1991, Journal of bacteriology.

[34]  A. Tomasz,et al.  Stable classes of phenotypic expression in methicillin-resistant clinical isolates of staphylococci , 1991, Antimicrobial Agents and Chemotherapy.